Cephalalgia

Papers
(The H4-Index of Cephalalgia is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-03-01 to 2025-03-01.)
ArticleCitations
Late Breaking Author Index100
Timing of headache after COVID-19 vaccines and its association with cerebrovascular events: An analysis of 41,700 VAERS reports81
Hypersensitivity to CGRP as a predictive biomarker of migraine prevention with erenumab65
A reply, drug-induced reversible cerebral vasoconstriction syndrome: Lessons from the real world62
Abstracts of the 20th Biennial Migraine Trust International Symposium, London UK, 5th to 8th September 202460
The incremental burden and healthcare resource utilization among people with migraine in Europe: Insights from the 2020 European National Health and Wellness Survey55
Development of a text message-based headache diary in adolescents and children54
Grey matter structure within the visual networks in migraine with aura: multivariate and univariate analyses51
Intravenous lacosamide and phenytoin for the treatment of acute exacerbations of trigeminal neuralgia: A retrospective analysis of 144 cases49
Author Index49
CLOCK gene circannual expression in cluster headache47
A male-specific mechanism of meningeal nociceptor sensitization promoting migraine headache46
Insights from triggers and prodromal symptoms on how migraine attacks start: The threshold hypothesis43
International Classification of Headache Disorders-4 – Work in Progress 141
Treatment patterns and characteristics of headache in patients in Japan: A retrospective cross-sectional and longitudinal analysis of health insurance claims data41
Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial41
Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review38
Other primary headaches: Distinct clinical features and uncertain pathophysiology37
Harassment in the headache field: a global web-based cross-sectional survey37
Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-ana33
Distinguishing persistent post-traumatic headache from migraine: Classification based on clinical symptoms and brain structural MRI data33
Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex32
Visual snow syndrome or “what's in a name?”31
Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials28
Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks27
Longitudinal differences in iron deposition in periaqueductal gray matter and anterior cingulate cortex are associated with response to erenumab in migraine27
Activation of the trigeminal system as a likely target of SARS-CoV-2 may contribute to anosmia in COVID-1926
Localized and widespread pressure pain hypersensitivity in patients with episodic or chronic migraine: A systematic review and meta-analysis26
Inhibiting PAC1 receptor internalization and endosomal ERK pathway activation may ameliorate hyperalgesia in a chronic migraine rat model26
CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine26
Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study26
0.03490686416626